Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Relay Therapeutics Inc’s stock clocked out at $2.00, down -12.66% from its previous closing price of $2.29. In other words, the price has decreased by -$12.66 from its previous closing price. On the day, 3.24 million shares were traded. RLAY stock price reached its highest trading level at $2.24 during the session, while it also had its lowest trading level at $1.99.
Ratios:
To gain a deeper understanding of RLAY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.95 and its Current Ratio is at 15.95. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on September 10, 2024, Upgraded its rating to Buy and sets its target price to $16 from $10.60 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 27 ’25 when Bergstrom Donald A sold 986 shares for $2.84 per share. The transaction valued at 2,800 led to the insider holds 615,052 shares of the business.
Rahmer Peter sold 247 shares of RLAY for $701 on Mar 27 ’25. The insider now owns 402,184 shares after completing the transaction at $2.84 per share. On Mar 27 ’25, another insider, Catinazzo Thomas, who serves as the Chief Financial Officer of the company, sold 4,864 shares for $2.84 each. As a result, the insider received 13,814 and left with 374,567 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 339044000 and an Enterprise Value of -393777312. For the stock, the TTM Price-to-Sale (P/S) ratio is 33.87 while its Price-to-Book (P/B) ratio in mrq is 0.43. Its current Enterprise Value per Revenue stands at -39.35 whereas that against EBITDA is 1.036.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.71, which has changed by -0.72183585 over the last 52 weeks, in comparison to a change of -0.024663687 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $10.72, while it has fallen to a 52-week low of $2.26. The 50-Day Moving Average of the stock is -44.74%, while the 200-Day Moving Average is calculated to be -64.42%.
Shares Statistics:
It appears that RLAY traded 2.40M shares on average per day over the past three months and 2618730 shares per day over the past ten days. A total of 167.76M shares are outstanding, with a floating share count of 127.71M. Insiders hold about 24.67% of the company’s shares, while institutions hold 80.03% stake in the company. Shares short for RLAY as of 1741910400 were 19121771 with a Short Ratio of 7.95, compared to 1739491200 on 15789969. Therefore, it implies a Short% of Shares Outstanding of 19121771 and a Short% of Float of 13.639999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Relay Therapeutics Inc (RLAY) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.24 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$1.47 and -$2.6 for the fiscal current year, implying an average EPS of -$2.1. EPS for the following year is -$2.19, with 7.0 analysts recommending between -$1.43 and -$2.83.
